Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von BMO Capital Markets 

Intellia Therapeutics Inc diskutieren

Intellia Therapeutics Inc

WKN: A2AG6H / Symbol: NTLA / Name: Intellia / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

11,88 €
1,41 %

27 6
27
6

Intellia Therapeutics (NTLA) was upgraded by William Blair from "market perform" to "outperform".
Ratings data for NTLA provided by MarketBeat

William Blair 
0
Melden Teilen
02.03.26 Buy -9,25 %
Einschätzung Buy
Rendite (%) -5,15 %
Kursziel 25,65
Veränderung
Endet am 03.03.27

Intellia Therapeutics (NTLA) had its price target raised by HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat

HC Wainwright 
0
Melden Teilen
03.03.26
Einschätzung Buy
Rendite (%) -3,13 %
Kursziel 24,79
Veränderung
Endet am 03.03.27

Intellia Therapeutics (NTLA) had its price target raised by Leerink Partners from $27.00 to $29.00. They now have an "outperform" rating on the stock.
Ratings data for NTLA provided by MarketBeat

SVB Leerink LLC 
0
Melden Teilen
03.03.26

Intellia Therapeutics (NTLA) had its "buy" rating reaffirmed by Brookline Capital Acquisition Corp..
Ratings data for NTLA provided by MarketBeat

Brookline Capital Acquisition Corp. 
0
Melden Teilen
03.03.26 Buy -4,38 %
Einschätzung Buy
Rendite (%) -0,92 %
Kursziel 41,04
Veränderung
Endet am 03.03.27

Intellia Therapeutics (NTLA) had its price target lowered by Canaccord Genuity Group Inc. from $54.00 to $48.00. They now have a "buy" rating on the stock.
Ratings data for NTLA provided by MarketBeat

Canaccord Genuity Group Inc. 
0
Melden Teilen
03.03.26
Einschätzung Buy
Rendite (%) -0,34 %
Kursziel 25,00
Veränderung
Endet am 04.03.27

Intellia Therapeutics (NTLA) was upgraded by JonesTrading from "hold" to "buy". They now have a $29.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat

Jonestrading 
0
Melden Teilen
15:00
Noch kein Mitglied? Jetzt kostenlos registrieren!

Neueste Beiträge

TD_Cowen in B + G Foods diskutieren, B + G Foods
B&G Foods (BGS) had its "sell" rating reaffirmed by T...
20:15
Cantor_Fitzgerald in Amaresco Inc. A diskutieren
Ameresco (AMRC) had its "overweight" rating reaffirmed by...
20:15
Citigroup_Inc_ in Scholar Rock Holding diskutieren
Scholar Rock (SRRK) had its price target raised by Citigr...
19:45
BMO_Capital_Markets in Scholar Rock Holding diskutieren
Scholar Rock (SRRK) had its price target raised by BMO Ca...
19:15
B__Riley_Financial__ in Amaresco Inc. A diskutieren
Ameresco (AMRC) had its price target raised by B. Riley F...
18:00
Wells_Fargo___Compan in California Resources Corp diskutieren
California Resources (CRC) had its price target raised by...
17:00
Bank_of_America_Co_ in Group 1 Automotive diskutieren
Group 1 Automotive (GPI) is now covered by Bank of Americ...
17:00
UBS_Group_AG in Crowdstrike Holdings Inc diskutieren, CrowdStrike Holdings Inc
CrowdStrike (CRWD) had its price target lowered by UBS Gr...
17:00
Mehr anzeigen